RIA
OTLK icon

Realta Investment Advisors’s Outlook Therapeutics OTLK Stock Holding History

Realta Investment Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-550
Closed -$20K – 425
2022
Q1 		$20K Hold
550
– – ﹤0.01% 425
2021
Q4 		$15K Sell
550
-250
-31% -$8.92K ﹤0.01% 417
2021
Q3 		$35K Buy
800
+250
+45% +$12.1K 0.01% 405
2021
Q2 		$27K Sell
550
-50
-8% -$2.32K 0.01% 395
2021
Q1 		$27K Sell
600
-150
-20% -$5.74K 0.01% 373
2020
Q4 		$20K Buy
750
+250
+50% +$5.22K 0.01% 329
2020
Q3 		$7K Hold
500
– – ﹤0.01% 317
2020
Q2 		$13K Buy
+500
New +$8.92K ﹤0.01% 341
2020
Q1 		– Sell
-250
Closed -$5K – 1050
2019
Q4 		$5K Hold
250
– – ﹤0.01% 1344
2019
Q3 		$7K Hold
250
– – ﹤0.01% 1228
2019
Q2 		$10K Buy
250
+187
+297% +$8.71K ﹤0.01% 1146
2019
Q1 		$9K Buy
+63
New +$8.9K ﹤0.01% 934

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
VF
Vista Finance Clayton, Missouri $179M AUM 18.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Realta Investment Advisors's OTLK Position: Q2 2022 in Review

Realta Investment Advisors sold out of Outlook Therapeutics (OTLK) in Q2 2022, closing a stake of 550 shares — an estimated $20K sold.

Realta Investment Advisors first reported a position in OTLK in Q1 2019 and held it in 12 quarters. The position peaked at $35K in Q3 2021. 75 funds tracked by Wall St. Rank hold OTLK as of Q2 2022.

  • Realta Investment Advisors reported no remaining Outlook Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Realta Investment Advisors sold 550 Outlook Therapeutics shares in Q2 2022, an estimated $20K.
  • Realta Investment Advisors first reported a position in Outlook Therapeutics in Q1 2019 and held it in 12 quarters.
  • Realta Investment Advisors's Outlook Therapeutics position peaked at $35K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2022.

Based on Realta Investment Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.